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Thromboxane synthetase inhibition with CGS 
13080 improves coronary blood flow after 
streptokinase-induced thrombolysis 
The focus of thls investlgatlon was to examine the potential beneficial effects of the selective 
thromboxane synthetase inhibitor CGS 13080 (imidazo [1,5-a] pyridins)hexanoic acid) on 
coronary blood flow after streptoklnasslnduced thrombolysls. Thrombotic occlusion of the 
circumflex coronary artery was produced by electrolytic (100 pA anodal current) injury to the 
intimal surface of the circumflex coronary artery at the site of a noncircumferential stenosis in 
dogs anesthetlred with pentobarbital to have open-chest surgery. lntracoronary streptokinase, 
8000 W/kg in 3 ml saline solution, was infused at 0.05 mi/min for 1 hour, beginning 30 minutes 
after the formation of an occlusive thrombus. The animals were assigned randomly to two 
groups. In group I (n = 10) the intravenous infusion of vehicle was begun simultaneously with the 
intracoronary administration of streptokinase and continued for 2 hours after thrombolysis had 
been achieved. The animals in group II (n = 10) received intravenous CGS 13080 (1 mg/kg/hr) 
along wlth intracoronary streptokinase. Infarct size was assessed by a dual perfusion technique 
with Evans blue and triphenyltetrarolium stalns to demarcate the normally perfused myocardlum 
from the area at risk and the infarct zone within the risk region. The two groups did not differ 
with respect to baseline coronary blood flow, time to the development of coronary artery 
thrombotic occlusion, or time to achieve thrombolysis. Oscillations in coronary biood flow were 
more frequent in group I than in group II (group I, 9 + 2.2; group II, 4.4 _+ 0.8 
oscillation/min x 100, p < 0.05 [mean * SEMI). Reocclusion was observed more frequently in 
group I than in group II (8 of 10 [80%] vs 2 of 10 [20%1, p < 0.05). Infarct size expressed as a 
percent of the total left ventricular mass was similar ([WLV) group I, 5% * 2%; group II, 
4% + l%), as was the percent of the left ventricle dependent on the blood flow distribution from 
the left circumflex coronary artery or the area at risk of infarction ([AFVLV) 37% + 2% vs 
40% -r- 3%, respectively). These results demonstrate that the thromboxane synthetase inhibitor 
CGS 13080, in combination with the thrombolytic agent streptokinase, is able to maintain 
patency of the injured coronary artery after thrombolysis and to decrease the frequency of 
oscillatory flow responses. The results suggest a possible role for thromboxane as a contributor 
to the process of thrombotic reocclusion after successful thrombolysis. (AM HEART J 
1987;113:1345.) 
Judith K. Mickelson, M.D., Paul J. Simpson, B.S., Mennen T. Gallas, B.S., and 
Benedict R. Lucchesi, Ph.D., M.D., Ann Arbor, Mich. 
The early treatment of an evolving myocardial 
infarction with thrombolytic therapy, as with strep- 
tokinase, has become accept.ed.ls2 The intracoronary 
administration of streptokinase provides an effec- 
tive means of inducing thrombolysis, but the time 
frame for limiting irreversible myocardial injury and 
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ultimate infarct size makes early intravenous 
administration of a thrombolytic agent a more prac- 
tical approach to the preservation of the jeopardized 
myocardium.3 Despite the success in affecting 
thrombolysis and myocardial reperfusion, reocclu- 
sion of the recantdized coronary artery is a frequent 
occurrence.’ Failure to maintain coronary artery 
patency may result from continued platelet aggrega- 
tion, coronary artery spasm, or “no reflow” in the 
distal region of the coronary vascular bed,6 In an 
effort to maintain vessel patency, anticoagulation 
and antiplatelet drugs are generally accepted as 
important adjunct.43 to thrombolytic therapy.” 
The selective thromboxane synthetase inhibitor 
CGS 13080 (imidazo [l&a] pyridined-hexanoic 
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Fig. 1. Instrumentation of coronary artery. Proximal 2 
cm of left circumflex coronary artery were isolated and 
instrumented proximal to distal (inset) with infusion 
cannula, electromagnetic flow probe, stimulation elec- 
trode, and screw occluder. 
acid) may be an acceptable adjunct to thrombolytic 
therapy in view of the realization that thromboxane 
may play a role in facilitating platelet aggregation in 
response to vessel wall injury. CGS 13060 has been 
shown to inhibit thromboxane synthesis by platelets 
and to prolong the bleeding time.’ These changes 
may be related to the ability of CGS 13060 to 
achieve a shunting of prostaglandin endoperoxide 
metabolism toward endogenous prostacyclin biosyn- 
thesis, as determined by the appearance of increased 
metabolic products (PGE,, 6-keto PG&,, and the 
urinary metabolite, 2,3-dinor-6-keto PGF,2s). In 
the in vivo setting the increased synthesis of prosta- 
cyclin may have significant coronary vasodilator and 
platelet antiaggregate properties that could serve to 
improve and maintain coronary blood flow after 
recanalization is established with a thrombolytic 
agent. 
Infusion of CGS 13060 to anesthetized dogs 
undergoing open-chest surgery was effective in pre- 
venting coronary artery thrombus formation at the 
site of intimal injury. lo This antithrombotic effect 
was accompanied by decreased ex vivo platelet 
we&ion after arachidonic acid stimulation and a 
marked decrease in thrombin-induced tbromboxane 
B, generation in whole blood. CGS 13060 in venous 
whole blood of dogs also promotes endoperoxide 
shunting with increases in PGE, and 6-k&o PGFla.ll 
Both human and animal studies demonstrate that 
the selective thromboxane synthetase inhibitor CGS 
13080 inhibits thromboxane production and 
enhances prostacyclin synthesis, suggesting that it 
may he effective in increasing vessel patency after 
streptokinase-induced thrombolysis. In the present 
study an experimental animal model of thrombosis- 
thrombolysis was employed, in which injury by 
electric stimulation of the intimal surface of the left 
circumflex coronary artery at the site of a moderate, 
fixed stenosis led to the development of an occlusive 
thrombus.12 The results of this investigation demon- 
strate that the thromboxane synthetase inhibitor 
CGS-13030 reduced the frequency of rethrombosis 
and improved the pattern of coronary artery blood 
flow after successful recanalization of the throm- 
bosed vessel with streptokinase. 
METHODS 
Thrombosis-thrombolysis myocardial injury. Twenty- 
seven male mongrel dogs (16 to 23 kg) were anesthetized 
with pentobarbital sodium (30 mg/kg intravenously), intu- 
bated and ventilated with room air at a tidal volume of 30 
ml/kg and a frequency of I2 breaths/min (Harvard respi- 
rator, Harvard Apparatus, S. Natick, Mass.). The left 
carotid artery and internal jugular vein were exposed, and 
catheters were inserted for monitoring arterial pressure 
(Statham P23 DC pressure transducer, Gould Inc., Car- 
diovascular Products, Oxnard, Calif.) and infusion of 
drugs, respectively. A left thoracotomy was performed in 
the fifth intercostal space, and the heart was suspended in 
a pericardial cradle. A catheter was advanced from the left 
atrium into the left ventricle for monitoring left ventricu- 
lar pressure. A 2 cm section of the left circumflex coronary 
artery was isolated proximal to the first obtuse marginal 
branch and instrumented proximal to distal as follows: 
infusion cannula, electromagnetic flow probe (Model 501 
Carolina Medical Electronics, Inc., King, N.C.), stimula- 
tion electrode, adjustable mechanical occluder (Fig. 1). A 
Tygon catheter (0.03 cm, internal diameter) was attached 
to a 26-gauge hypodermic needle tip that was formed into 
a U shape and inserted into the proximal portion of the 
coronary artery and used as the intracoronary infusion 
cannula. The stimulation electrode was constructed from 
a 25-gauge hypodermic needle tip attached to a 30-gauge 
Teflon-insulated silver-coated copper wire. The mechani- 
cal occluder was constructed of stainless steel in a C shape 
with a Teflon screw (2 mm diameter), which could be 
manipulated to control vessel circumference. The occluder 
was adjusted to decrease the reactive hyperemic flow by 
50% to 70% without affecting mean resting coronary 
blood flow. The small intervening coronary branches over 
the 1 to 2 cm segment were ligated. 
Continuous recordings of blood pressure, left ventricu- 
lar pressure, rate of rise in left ventricular pressure, lead II 
ECG, and mean and phasic left circumflex coronary artery 
blood flow were obtained on a model 7 polygraph (Grass 
Instrument Co., Quincy, Mass.). Zero flow and hyperemic 
flows were determined by occluding the circumflex coro- 
nary artery distal to the flow probe for 10 seconds. The 
flow probe was calibrated with heparinized whole blood. 
Thirty minutes after surgical preparation, a 100 ,uA con- 
tinuous anodal direct current stimulation was initiated 
and maintained until the circumflex coronary artery blood 
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flow decreased to and remained at 0 ml/min for 30 
minutes. The anodal direct current was delivered from a 9 
V nickel-cadmium battery with the anode connected in 
series via a 250,000 R potentiometer to the intraluminal 
coronary artery electrode. The electric circuit was com- 
pleted by placing the cathode in a subcutaneous site. At 
the time of thrombotic coronary artery occlusion, 30 mg of 
lidocaine hydrochloride was given intravenously, and the 
animal was observed for an additional 30 minutes, during 
which time blood flow in the left circumfiex coronary 
artery remained at the predetermined calibrated point for 
zero flow. Intracoronary streptokinase (6000 W/kg in 3 ml 
normal saline solution) was infused at a rate of 0.05 
ml/min over a period of 60 minutes. Dogs were assigned 
randomly to two groups. In group I, 50 ml of vehicle (5% 
dextrose in water) was infused intravenously over 2 hours, 
beginning simultaneously with the intracoronary infusion 
of streptokinase. The animals randomly assigned to group 
II received CGS 13080 (imidazo [1,5-l] pyridine-5-hexa- 
noic acid, Ciba-Geigy) 1 mg/kg/hr intravenously in 50 ml 
of vehicle while streptokinase was given via the intracor- 
onary cannula. Two hours after reestablishing coronary 
artery reperfusion, the heart was fibrillated electrically 
and removed quickly for postmortem quantification of 
infarct size. 
Only dogs that survived 2 hours after coronary artery 
reperfusion was established were included in the final data 
analysis. Six dogs fibrillated <30 minutes after coronary 
artery thrombosis and were not successfully resuscitated 
(fewer than three defibrillation attempts), 1 dog fibril- 
lated during reperfusion with streptokinase alone and was 
not successfully resuscitated, and one dog fibrillated 
during streptokinase and CGS 13080 infusion and was 
successfully defibrillated. 
Postmortem quantification of infarct size. Myocardial 
infarct size was quantified with an in vitro dual perfusion 
method described previously.13 Cannulas were inserted 
into the circumflex coronary artery at the site of the 
stenosis and into the aorta above the coronary ostia. The 
circumflex distribution was perfused with 1.5% triphenyl- 
tetrazolium hydrochloride in 20 mmol potassium phos- 
phate buffer (pH 7.4, 38” C). The coronary ostia were 
perfused with 0.25% Evan’s blue stain via the aortic 
cannula. Both the circumflex region and the remainder of 
the heart were perfused with the respective histochemical 
reagents at a constant pressure of 100 mm Hg for 5 
minutes at 37” C. The heart was cut into six equal 
sections, 1.0 cm thick, perpendicular to the apex-base axis. 
The area of the left ventricle at risk for infarction because 
of its anatomic dependence on the circumflex coronary 
artery for blood flow was identified by the absence of 
Evan’s blue stain. The region of infarcted myocardium 
within the area at risk was demarcated by the inability to 
react with triphenyltetrazolium hydrochloride and 
remained pale in color in contrast to the deep red color- 
ation imparted by the formazan precipitate of the reduced 
tertazolium sa1t.14r15 Transverse ventricular sections were 
traced onto clear plastic overlays. Planimetry was used to 
determine the total left ventricular area, the area at risk, 
Table 1. Characteristics of coronary blood flow during 
thrombosis-thrombolysis myocardial injury 









Group I* Group II* 
83 k 14 (10) 73 + 13 (10) 
26 iz 6 (10) 21 + 4 (10) 
17 + 5 (8) 15 * 15 (2) 
8 (10) 2 uw 
9.0 * 2.2 (10) 4.4 * 0.8 (1o)t 
Data are mean + SEM. 
*Number studied in parentheses. 
tp < 0.05. 
and the area of myocardium that had undergone irrevers- 
ible injury. Ventricular sections were trimmed of right 
ventricular, valvular, and fatty tissue and were weighed. 
Infarct size was expressed as a percent of the anatomic 
area at risk and the total left ventricle. In a previous study, 
gravimetric analysis agreed closely with determinations of 
infarct size obtained from planimetry of the overlay 
tracingsI 
Reperfusion coronary b!ood flow. Mean left circum- 
flex coronary blood flow, as determined by the extracorpo- 
real electromagnetic flow probe, was plotted as a function 
of time during reperfusion at the following intervals: 0, 5, 
10, 15, 20, 25, 30, 35,60, 90, and 120 minutes. Oscillations 
in coronary blood flow, which occurred during reperfusion, 
appeared as cyclic decreases in mean blood flow to near 
zero flow, followed by abrupt increases in flow. These were 
quantitated by determining the number of oscillations per 
minute before flow decreased to zero, multiplying by the 
number of minutes (120), and arbitrarily multiplying the 
resulting number by 100. 
Statistical analysis. The data are expressed as the 
mean ? SEM. Differences between the two groups were 
determined by Student’s t test and were considered 
significant if p < 0.05. Differences within each group over 
time were determined by multiple pair wide comparisons 
(paired Student’s t test) with an experimental alpha level 
of 0.05 (with Bonferroni’s method). 
RESULTS 
Group characteristics. Twenty dogs were studied 
successfully in this thrombosis-thrombolysis model 
of myocardial injury (streptokinase + vehicle [group 
I, n = lo], strepbkinase + CGS 13080 [group II, 
n = lo]). Despite randomization, there was a small 
difference in the weights of the dogs between the 
two groups (group I, 20.7 + 0.6 kg; group II, $8.4 + 
0.6 kg; p < 0.05 [mean + SEMI). There were no 
significant differences in recorded hemodynamic 
parameters (heart rate, left ventricular pressure, 
blood pressure, coronary blood flow) determined 
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Fig. 2. Left circumflex coronary blood flow response. Blood flows were similar at baseline control (C) and 
decreased similarly 5 minutes after reperfusion (CA& in both groups. However, 2 hours after reperfusion 
(END), blood flow had improved in group II, streptokinase + CGS 13080 [l mg/kg/br (CGS-SK)], 
compared with group I, streptokinase + vehicle (p < 0.05). Data are mean + standard error. 
between the two groups at the beginning of the 
experiments. 
Coronary artery thrombosis, thrombolysis, and 
rethrombosis. The mean time required for the devel- 
opment of a fully occlusive thrombotic lesion in the 
left circumflex coronary artery as a result of electro- 
lytic injury to the intimal surface of the vessel did 
not differ significantly among the animals in each of 
the two groups: 83 + 14 vs 73 + 13 minutes in group 
I and group II, respectively. Coronary thrombolysis 
was achieved within a similar time frame in each of 
the dogs in groups I and II as a result of receiving 
streptokinase alone or in combination with CGS 
13080. The time to achieve reperfusion was 26 + 6 
minutes for group I vs 21 t 4 minutes for group II 
(p > 0.05). 
Despite the efficacy of intracoronary streptoki- 
nase in achieving recanalization of the thrombosed 
circumflex coronary artery, reocclusion of the vessel 
occurred when the l-hour infusion was completed, 
more frequently in the animals in group I (8 of 10, 
80%) as compared with those in group II (2 of 10, 
20 % ). The two dogs in group II, in which reocclusion 
did occur, did not differ from the group I dogs with 
respect to the time of reocclusion after discontinuing 
streptokinase (Table I). 
Coronary Artery blood t@w patterns. The develop- 
ment of an occlusive thrombus in the circumflex 
coronary artery resulted in a total and sustained 
reduction in blood flow (determined~with an electro- 
magnetic flow probe) in the distribution of the 
circumflex vessel. This was accompanied by discol- 
oration of the myocardium in the region of distribu- 
tion of the occluded vessel as well as ST-segment 
alterations in the lead II ECG consistent with the 
presence of acute myocardial ischemia and myocar- 
dial injury. Lysis of the occlusive thrombus was 
accompanied by a reactive hyperemia in the record- 
ed blood flow. The restoration of blood flow in the 
circumflex coronary artery was associated with a 
reversal of cyanosis of the myocardium in the region 
of distribution of the vessel and the appearance of 
ECG changes showing restoration in the ST segment 
and the onset of reperfusion arrhythmias. 
The control and resting circumflex coronary 
artery blood flows in each of the two groups, deter- 
mined with an electromagnetic flow probe, were 
similar before the initiation of an occlusive throm- 
bus. Once thrombolysis had been achieved, the 
coronary artery blood flows progressively decreased 
from the initial reperfusion value in group I, 14 _+ 
3.5 to 6 f 3.8 ml/min, which was significantly lower 
than the coronary blood flow before thrombotic 
occlusion, 33 -t 3.5, p < 0.001. In group II the initial 
coronary artery blood flow on reperfusion was less 
than baseline, 12 + 4 vs 32 If: 3.1 ml/min, p < 0.05, 
but improved steadily over the next 2 hours to 
18 + 5 ml/min (Fig. 2). The mean circumflex coro- 
nary artery blood -flow in group II was greater than 
that in group I 0, < 0.05) animals, which received 
only streptokinase, when the study was terminated 2 
hours after the initial recanalisation had been 
achieved. 
The characteristic coronary artery blood flow 
patterns diiered between the two groups of animals. 
The number of oscillations in the circumflex coro- 
nary artery blood flow were more frequent in the 
streptokinase treated group as compared with the 
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q SK THROMBOLYSIS (n=lO) 
Rd CGS-SK THROMBOLYSIS (n =l 0) 
WAR IZ/LV AWLV 
Fig. 3. Myocardial infarct size. Quantitation of infarct 
size is expressed with respect to infarct zone (ZZ) as a 
percent of area of left ventricle at risk (AR) and as percent 
of total left ventricle (LV) after histochemical demarca- 
tion of respective myocardial regions. There was no differ- 
ence in infarct size between the two groups: group 
I = streptokinase + vehicle (SK), and group II = strepto- 
kinase + CGS 13080 (1 mg/kg/hr [CGS-SK]). 
animals that received streptokinase along with CGS 
13080 (Table I, p < 0.05). The increased incidence of 
oscillations correlated with an increased incidence of 
reocclusion. Two hours after initial recanalization 
had been achieved, only 2 of 10 dogs in group I as 
compared with 8 of 10 dogs in group II 0, < 0.05) 
continued to manifest pulsatile flow recordings in 
the circumflex coronary vessel as determined with 
an electromagnetic flow probe placed proximal to 
the site of the external mechanical constrictor. 
Effects of reperfusion on myocardial infarct size. 
The areas of the left ventricle at risk for infarction 
(AR/LV) were similar in the two groups, demon- 
strating that the anatomic dependence on the prox- 
imal circumflex coronary artery was similar (Fig. 3). 
Tbe infarct sizes expressed as a percentage of the 
area at risk @Z/AR) or as a percent of the total left 
ventricle (IZILV) were similar for the two groups. 
However, infarct size determined after 2 hours of 
reperfusion must be interpreted with caution.17 In 
group I most coronary arteries had reoccluded less 
than 1 hour before determination of infarct size, and 
the extent of this second ischemic insult may not 
have been fully apparent. The increased incidence of 
reocclusion prolonged the total duration of the 
coronary artery blood flow deficit in the dogs in 
group I as compared with those in group II (Group I, 
109 -+ 9 minutes; group II, 52.5 * 4 minutes; 
p < 0.001). 
Hemodynamic responses. In both groups the main 
hemodynamic parameters (heart rate and blood 
pressure) remained essentially unchanged through- 
out the experiment (Fig. 4). The heart rate was 
ti d 160 
:a = = I% 120 3s 3 80 
=5 
230 
0 CGS-SK THROMBOLYIS (nzl0) 
Cl SK THROMBOLVSIS (n-10) 
i= cio CAR Eim 
Fig. 4. Hemodynamic responses. Over the course of the 
experiment there was no difference in heart rate or mean 
arterial blood pressure between the two groups: group 
I = streptokinase (SK) + vehicle, and group II = strepto- 
kinase + CGS 13080 (1 mg/kg/hr [CGS-SK]). Time points 
are C = baseline control, CA0 = 15 minutes after coronary 
artery occlusion, CAR = 5 minutes after initial reperfu- 
sion, END = 2 hours after initial reperfusion. 
slightly faster in group II before the induction of 
thrombosis (group I, 158 * 9 vs group II, 174 +- 8; 
p > 0.05). The blood pressure was slightly lower in 
group II during the thrombotic occlusion, but by the 
end of the 2-hour reperfusion the blood pressure was 
slightly higher than group I (Group I, 115 & 7 to 
106 -+ 7 mm Hg vs group II, 104 + 14 to 112 2 9 
mm Hg; p > 0.05). None of the differences in the 
hemodynamic parameters at the recorded intervals 
varied significantly. 
DISCUSSION 
Maintenance of thrombolysis. The intracoronary 
infusion of streptokinase, beginning 30 minutes 
after thrombotic occlusion, was effective in reesta- 
blishing left circumflex coronary artery blood flow 
within 30 minutes in each of the 20 animals included 
in this study. During the 2-hour reperfusion period, 
despite initial tbrombolytic therapy, mean coronary 
blood flow was significantly less than the baseline 
flows in each of the groups. Furthermore, coronary 
blood flow in the recanalized vessel declined pro- 
gressively in the group I animals compared with 
those in group II. This observation would suggest 
that the ability to maintain and autoregulate coro- 
nary artery blood flow in the stenosed, recanalized 
1350 Mickelson et al. 
June 1987 
American Heart Journal 
vessel was benefited by the addition of CGS 13080 to 
the thrombolytic regimen. 
Frequent oscillations in coronary blood flow 
occurred in 8 of the 10 dogs in group I that had 
undergone successful coronary artery thrombolysis 
and that had reocclusion early after discontinuation 
of the intracoronary administration of streptoki- 
nase. Although streptokinase was effective initially 
in restoring myocardial blood flow, it did not alter 
the thrombogenic potential of the injured vascular 
endothelial surface. Thus reocclusion of the injured 
vessel was common among the animals in group I 
and was preceded by frequent oscillations in coro- 
nary artery blood flow. The repetitive oscillatory 
events might indicate the persistence of platelet 
aggregation, enhanced vasomotor activity, or inter- 
mittent occurrences of the no reflow phenomenon in 
the distal coronary vascular bed. 
The administation of the thromboxane synthetase 
inhibitor CGS 13680 was associated with an overall 
enhancement in the coronary artery blood flow 
throughout the period of observation, after having 
achieved thrombolysis. Most important was the 
finding that the administration of CGS 13080 pre- 
vented reocclusion in 8 of 10 dogs that had been 
recanalized with streptokinase, as opposed to the 
animals in group I, in which only 2 of 10 dogs were 
capable of maintaining vessel patency for the dura- 
tion of the study protocol. 
Possible mechanism for the beneficial effect of CGS 
~3080. Thromboxane synthetase inhibitors have 
permitted the transfer of platelet-derived prosta- 
glandin endoperoxides to endothelial cells for the 
synthesis of prostacyclin. 18.1e The synthesis of pros- 
tacyclin from platelet-derived endoperoxides has 
been demonstrated by incubating platelets with 
endothelial cell cultures treated with aspirin so as to 
inhibit the endogenous formation of prostanoids by 
the cultured ce11s20 Furthermore, the transfer of 
cyclic endoperoxides is unidirectional, i.e., recipro- 
cal transfer of the endoperoxides from endothelium 
to platelets does not result in thromboxane A, 
production. 21 It is hypothesized that the inhibition 
of platelet thromboxane synthetase by CGS 13080 
would provide additional amounts of the endoperox- 
ides to serve as substrate for the synthesis of prosta- 
cyclin by other cells, i.e., endothelial cells and 
leukocytes. Experimental support for this conclu- 
sion has been provided recently by Mehta et al.” 
who demonstrated the production of prostacyclin by 
neutrophii in the presence of platelets and throm- 
boxane synthetase inhibition by CGS 13080. In our 
laboratory, Simpson et al.*O have demonstrated that 
the addition of CGS 13080 to collagen-activated 
whole blood in vitro leads to a marked increase in 
prostacyclin metabolites 6-keto PGF1, and PGE, 
and decreased thromboxane B, production com- 
pared with blood samples with no thromboxane 
synthetase inhibitor. Furthermore, they found that 
thrombin-stimulated thromboxane generation in 
whole blood was prevented with CGS 13080 (control, 
46.7 + 18.2 rig/ml [n = lo]; CGS 13080, 1.7 + 0.7 
rig/ml [n = lo]; p < 0.05). 
It is proposed that the beneficial effect of CGS 
13080 in reducing the frequency of the oscillatory 
coronary artery flow pattern and in maintaining 
coronary artery blood flow after thrombolysis may 
be related to an enhancement of regional prostacy- 
clin synthesis by the vascular end&helium as a 
result of endoperoxide shunting localized to the 
vascular site, at which the residual thrombus mass 
remains adherent to the injured vessel wall. The 
establishment of a “microenvironment” formed by 
the blood cells that constitute the thrombus mass at 
the interface, where the thrombus attaches to the 
vessel wall, provides an opportunity for maximal 
exchange of platelet endoperoxides with other cells 
in the thrombus and with the surviving endothelial 
cells. The resulting synthesis of prostacyclin and 
perhaps other prostanoids would affect the ability of 
the residual thrombus mass from serving as a nidus 
for the continued formation of the occlusive lesion 
and reocclusion of the vessel. 
Prostacyclin may reduce the potential for throm- 
bus formation by several different mechanisms. It 
causes disaggregation of aggregated platelets by 
increasing platelet cyclic adenosine monophosphate 
(CAMP). Thromboxane synthetase inhibition alone 
does not change platelet CAMP concentrations, 
whereas thromboxane A, decreases CAMP and 
results in platelet activation. Inhibition of thrombo- 
xane synthetase alone would not be expected to 
prevent platelet aggregation by stimuli that can 
directly alter platelet CAMP (collagen, adenosine 
diphosphate). Futhermore, thromboxane synthetase 
inhibition would not promote CAMP-dependent dis- 
aggregation. g,lo Another known effect of prostacyclin 
on platelet function is to inhibit platelet prothrom- 
binase activity. 22 In the absence of prothrombinase, 
the conversion of prothrombin to thrombin would 
not occur, thereby impairing the conversion of 
fibrinogen to fibrin. The net result is to alter the 
formation and stabilization of an organized throm- 
bus mass capable of occluding the injured blood 
vessel. 
Among the reported actions of prostacyclin is a 
profibrinolytic action leading to the release of plas- 
minogen activator. In patients with peripheral vas- 
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cular disease, prostacyclin caused release of tissue 
plasminogen activator and a shortened euglobulin 
lysis time.23 When the actions of prostacyclin are 
viewed together, the prostanoid predominantly 
inhibits the coagualtion cascade. 
Despite the duration of coronary artery occlusion 
being different in groups I and II, infarct size in the 
two groups did not differ significantly. The initial 
occlusion time included the 30-minute period 
allowed in the protocol for stabilization of the 
occlusive thrombus, plus the time necessary for 
streptokinase-induced reperfusion to be established. 
Because there were few reocclusions in group II, this 
was the total occlusion time for dogs receiving CGS 
13080 in addition to streptokinase. In group I, 
streptokinase alone, 80% of the coronary arteries 
reoccluded, resulting in a significantly greater total 
occlusion time. Infarct size assessed by the dual 
perfusion technique with Evan’s blue stain and 
triphenyltetrazolium 1 hour after reocclusion may 
have underestimated the total extent of irrversible 
injury when only streptokinase was infused. The 
time necessary for detection of infarction by tetrazo- 
lium, while often a subject of controversy, may be as 
short as 2 hours in the presence of regional reperfu- 
sion. 17*24 In the group that received streptokinase 
plus CGS 13080, 80% of the recanlized vessels 
remained patent. We did not observe a difference 
between the two groups with respect to ultimate 
infarct size, which may be related to the fact that the 
duration of regional myocardial ischemia was not of 
sufficient duration to permit full expression of dam- 
age in the risk region, thereby limiting our ability to 
detect significant differences between the two treat- 
ment groups. Furthermore, the determination of 
infarct size reduction in either of the groups may 
have been made difficult by virture of the fact that 
both CGS 13080 and streptokinase may he able to 
protect the ischemic myocardium against the devel- 
opment of irreversible injury. Burke et a1.25 found 
that plasma creatine kinase concentrations and 
myocardial creatine kinase depletion in the infarct 
zone were reduced when CGS 13080 was infused 
during left anterior descending coronary artery liga- 
tion in cats. In several experimental models, strepto- 
kinase, independent of its thrombolytic activity, had 
positive effects on the globally ischemic myocardi- 
Of interest are the recent studies by Mehta et al.,” 
describing CGS 13080 as having activity that inhib- 
its thromboxane production and allows neutrophils 
to form prostacyclin from the platelet-derived cyclic 
endoperoxides. Prostacyclin has also been shown to 
limit infarct size by inhibition of neutrophil activa- 
tion.% These are relevant issues, since limitation of 
infarct size, when reperfusion is induced by throm- 
bolytic therapy, will probably require an agent that 
can mitigate the accelerated inflammatory response. 
Reperfusion of ischemic myocardium is accompa- 
nied by a neutrophil infiltration that may be a major 
contributor to the development of myocardial necro- 
sis. Thus the selective thromboxane synthetase 
inhibitor CGS 13080 has several clinically appealing 
properties. It may limit reperfusion injury by shunt- 
ing neutrophil prostanoid metabolism toward pros- 
tacyclin production, thereby modulating the damag- 
ing effect of the neutrophils infiltrating ischemic 
myocardium. In addition, CGS 13080 stabilizes and 
maintains regional myocardial blood flow by main- 
taining vessel patency during reperfusion after 
streptokinase-induced thrombolysis of a coronary 
artery thrombotic occlusion, despite the continued 














Gruppo Italian0 per lo Studio della Streptochinasi nell’infar- 
to Miocardioco (GISSI). Effectiveness of intravenous throm- 
bolytic treatment in acute myocardial infarction. Lancet 
1986;1:39?-401. 
Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Marnard C, 
Fritz JK. The Western Washington randomized trial of 
intracoronary streptokinase in acute myocardial infarction. N 
Engl J Med 1985;312:1073-8. 
Simoons ML, Brand MVD, Zwaan CD, et al. Improved 
survival after early thromholysis in acute myocardial infarc- 
tion. Lancet 1985;2:578-82. 
Gold HK, Leinbach RC, Palacios IF, et al. Coronary reocclu- 
sion after selective administration of streptokinase. Circula- 
tion 1983;68(suppl 1):150-4. 
Kloner RA, Alker KJ. The effect of streptokinase on intra- 
myocardial hemorrhage, infarct size, and the no-reflow phe- 
nomenon during coronary reperfusion. Circulation 1984; 
70:513-21. 
Schumacher WA, Lee EC, Lucchesi BR. Augmentation of 
streptokinase-induced thrombolysis by heparin and prosta- 
cyclin. J Cardiovasc Pharmacol 1985;7:739-46. 
Ku EC, McPherson SE, Signor C, Chertock H, Cash WD. 
Characterization of imidazo[l,5-alpyridine-5-hexanoic acid 
(CGS 13080) as a selective thromboxane synthetase inhibitior 
using in vitro and in viuo biochemical models. Biochem 
Biophys Res Commun 1983;112:899-906. 
MacNab MW, Foltz EL, Graves BS, et al. The effects of a new 
thromboxane synthetase inhibitor, CGS 13080, in man. J Clin 
Pharmacol 1984;24:76-83. 
Fitzgerald GA, Oates JA. Selective and nonselective inhibi- 
ti~~-ofth~omlj~liane f r ation, G n Pharrnu! The! 109d~ 
35:633-40. 
Simpson PJ, Smith CB, Rosenthal G, Lucchesi BR. Reduc- 
tion-in the incidence of canine coronary artery thrombosis by 
the thromboxane svnthetase inhibitor-CGS 13080. J Phar- 
macol Exp Ther 1986;238:497-501. 
Mehta J, Mehta P, Lawson DL, Ostrowski N, Brigmon L. 
Influence of selective thromboxane synthetase blocker CGS 
13080 on thromboxane and prostacyclin biosynthesis in 
whole blood: evidence for synthesis of prostacyclin by leuko- 
1352 Mickeison et al. 
Juno 1997 








cytes from platelet-derived endoperoxides. J Lab Clin Med 
1985;106%6-52. 
Romson JL, Haack DW, Lucchesi BR. Electrical induction of 
coronary artery thrombosis in the ambulatory canine: a 
model for in viuo evaluation of anti-thrombotic agents. 
Thromb l&s 1980;17:841-53. 
Romson J, Bush L, Jolly S, Lucchesi B. Cardioprotective 
effects of ibuprofen in experimental regional and global 
mvocardial ischemia. J Cardiovasc Pharmacol 1982:4:187. 
Fi&em MC, Meerbaum S, Rit J, et al. Early phase acute 
myocardial infarct sixe quantifications: validation of the 
triphenyl tetrazolium chloride tissue enzyme staining tech- 
nique. AM HEART J 1981;101:593-606. 
Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium 
staining of irreversible ischemic injury following coronary 
artery occlusion in rate. Am J Path01 1985;121:522. 
Jolly SR, Lucchesi BR. Effect of BW775C in an occlusion- 
reperfusion model of ischemic myocardial injury. AM HEART J 
1983;106:8-13. 
Schaper J, Schaper W. Reperfusion of ischemic myocardium: 
ultrastructural and hi&chemical aspects. J Am Co11 Cardiol 
1983;1:1037-46. 
Aiken JW, Shebuski RJ, Miller OV, Gorman RR. Endoge- 
nous prostacyclin contributes to the efficacy of a thrombo- 
xane synthetase inhibitor for preventing coronary artery 
thrombosis. J Pharmacol EXD Ther 1981:219:299-308. 
19. Needleman P, Wyche A, R& A. Platelet and blood vessel 
arachidonate metabolism and interactions. J Clin Invest 
1979;63:345-9. 








of prostacyclin from platelet-derived endoperoxides by cul- 
tured human endothelial cells. J Clin Invest 1980,66:979-86. 
Schafer AI, Crawford DD, Gimbrone MA. Unidirectional 
transfer of prostaglandin endoperoxides between platelets 
and endothelial cells. J Clin Invest 1984:73:1105-12. 
Zwaal RFA, Comfurius P, Hemker Hd, Bevers EM. The 
inhibition of platelet prothrombinase activity by prostacy- 
clin. Haemostasis 1984;14:320-4. 
Musial J, Wilczyska M, Sladek K, Cierniewski CS, Nizan- 
kowski R, Szczeklik A. Fibrinolytic activity of prostacyclin 
and iloprost in patients with peripheral arterial disease. 
Prostaglandins 1986,31:61-70. 
Lie JT, Pairolero PC, Halley KE, Titus JL. Macroscopic 
enzyme-mapping verification of large, homogenous, experi- 
mental myocardial infarcts of predictable size and location in 
dogs. J Thorac Cardiovasc Surg 1975;69:599-605. 
Burke SE, DiCola G, Lefer AM. Protection of ischemic cat 
myocardium by CGS 13080, a selective potent thromboxane 
A, synthesis inhibitor. J Cardiovasc Pharmacol 1983;5:842- 
7. 
Puckett SW, Digerness SB, Bowdon HR, Rogers WJ, Rackley 
CE. Direct effects of streptokinase on the isolated rat myo- 
cardium. J Cardiovasc Pharmacol 1984;6:1120-3. 
Fung AYM, Rabkin SW. Beneficial effects of streptokinase 
on left ventricular function after myocardial reoxygenation 
and reperfusion following global ischemia in the isolated 
rabbit heart. J Cardiovasc Pharmacol 1984;6:429-35. 
28. Simpson PJ, Mitsos SE, Ventura A, et al. Prostacyclin 
protects ischemic-reperfused myocardium in dogs by inhibi- 
tion of neutrophil activation. AM HEART J 1987;113:129-37. 
BOUND VOLUMES AVAILABLE TO SUBSCRIBERS 
I 
Bound volumea of the AMERICAN HEART JOURNAL are available to subscribers (only) for the 1987 issues from the 
Publisher at a coat of 345.66 ($56.66 int&national) for Vol. 113 (January-June) and Vol. 114 (Julv-December). Shinnine charges are _ La --~- 
included. Each bound volume containa a subject and author index and ah advertising is removed. Copies are shipped within 60 days 
after publication of the last issue in the v~hune. The binding is durable buckram with the journal name, volume number, and year 
stamped in gold on the spine. Payment must occompeny all orders. Contact The C. V. Moaby Company, Circulation Department, 
11630 Weathne Industrial Drive, St Louis, Miiuri 63146, USA; phone (666) 325-4177, ext. 351. 
Subscriptions muet be in fence to prroliiy. Bound volumes are not available in place of a regular Journal 
subscription. 
